Overall, while phytocannabinoids have several inherent challenges regarding drug delivery and off-target effects, it will be important to assess these hurdles and devise approaches that will allow the use of phytocannabinoids in SGLT2-based drugs for T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.